Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

Share Price is delayed by 15 minutes
Get Live Data
2.33    -0.01 (-0.43%)
Bid:
2.32
Ask:
2.35
Spread: 0.03 (1.293%)
Market Cap: $752.76m
RTW Live PriceLast checked at - London Stock Exchange

Intraday Rtw Biotech Share Chart

Monthly Valuation Update and Factsheet

16 Sep 2024 07:00

RNS Number : 2283E
RTW Biotech Opportunities Ltd
16 September 2024
 

LEI: 549300Q7EXQQH6KF7Z84

16 September 2024

RTW Biotech Opportunities Ltd

Monthly Valuation Update and Factsheet

-2.3% NAV movement for the month

RTW Biotech Opportunities Ltd (the "Company") announces that the unaudited net asset value attributable to the ordinary shares of the Company at the close of business on 31 August 2024 (the "NAV") was US$673.6 million, or US$2.01 per ordinary share, -2.3% from the previous month.

The monthly factsheet is available on the Company's website:

 

https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/factsheets-letters/

 

For Further Information

RTW Investments, LP

+44 20 7959 6361

Woody Stileman, Managing Director, Business Development

Krisha McCune, Director, Investor Relations

biotechopportunities@rtwfunds.com

 

 

Buchanan (PR & Communications Adviser)

 

 

+44 20 7466 5107

Charles Ryland

 

Henry Wilson

 

George Beale

 

 

 

Deutsche Numis (Joint Corporate Broker)

+44 20 7260 1000

Freddie Barnfield

 

Nathan Brown

 

Euan Brown

 

 

BofA Securities (Joint Corporate Broker)

+44 20 7628 1000

Edward Peel

 

Alex Penney

 

 

Cadarn Capital (Distribution & IR Partner)

 

+44 73 6888 3211

David Harris

 

 

Elysium Fund Management Limited

Joanna Duquemin Nicolle, Chief Executive Officer

Sadie Morrison, Managing Director

 

 

+44 14 8181 0100

Morgan Stanley Fund Services USA LLC

+1 914 225 8885

 

About Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.

***********

The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements, as well as those included in any related materials, are subject to risks, uncertainties and assumptions about the Company and/or its underlying investments, including, among other things, the development of the applicable entity's business, trends in its operating industry, expected use of financing proceeds and future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur.

The information contained in this announcement is given at the date of its publication (unless otherwise marked). No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.

***********

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCZELFFZKLZBBL
Date   Source Headline
5th Sep 20257:00 amRNSInclusion in FTSE All-Share Index
1st Sep 20257:00 amRNSTotal Voting Rights
22nd Aug 20257:00 amRNSTransaction in Own Shares
19th Aug 20257:01 amRNSNotice of Interim Results
19th Aug 20257:00 amRNSStrategic Funding Agreement with Aquestive
15th Aug 20257:00 amRNSTransaction in Own Shares
14th Aug 20257:00 amRNSMonthly Valuation Update and Factsheet
17th Jul 20257:00 amRNSUpdate on Kailera Therapeutics
15th Jul 20257:00 amRNSMonthly Valuation Update and Factsheet
10th Jul 20257:00 amRNSMerck to acquire Verona Pharma
3rd Jul 20255:34 pmRNSHolding(s) in Company
1st Jul 20257:00 amRNSTotal Voting Rights
26th Jun 20257:00 amRNSTransaction in Own Shares
25th Jun 20257:00 amRNSTransaction in Own Shares
24th Jun 20257:01 amRNSTransaction in Own Shares
24th Jun 20257:00 amRNSUpdate on Corxel Pharmaceuticals
23rd Jun 20257:00 amRNSTransaction in Own Shares
20th Jun 20257:00 amRNSTransaction in Own Shares
19th Jun 20257:00 amRNSTransaction in Own Shares
18th Jun 20257:00 amRNSTransaction in Own Shares
17th Jun 20257:00 amRNSTransaction in Own Shares
16th Jun 20257:00 amRNSTransaction in Own Shares
13th Jun 20257:00 amRNSTransaction in Own Shares
12th Jun 20257:01 amRNSTransaction in Own Shares
12th Jun 20257:00 amRNSMonthly Valuation Update and Factsheet
11th Jun 20257:00 amRNSTransaction in Own Shares
10th Jun 20257:00 amRNSTransaction in Own Shares
9th Jun 20254:00 pmRNSResult of AGM
9th Jun 20257:00 amRNSTransaction in Own Shares
6th Jun 20257:00 amRNSTransaction in Own Shares
5th Jun 20257:00 amRNSTransaction in Own Shares
4th Jun 20257:00 amRNSTransaction in Own Shares
3rd Jun 202511:00 amRNSDirector/PDMR Shareholding
3rd Jun 20257:00 amRNSTransaction in Own Shares
2nd Jun 20257:01 amRNSTotal Voting Rights
2nd Jun 20257:00 amRNSTransaction in Own Shares
30th May 20257:01 amRNSTransaction in Own Shares
30th May 20257:00 amRNSPortfolio Updates
29th May 20257:00 amRNSTransaction in Own Shares
27th May 20257:00 amRNSTransaction in Own Shares
22nd May 20257:00 amRNSTransaction in Own Shares
21st May 20257:00 amRNSTransaction in Own Shares
20th May 20257:00 amRNSTransaction in Own Shares
19th May 20257:00 amRNSUpdate on Rocket Pharmaceuticals
16th May 20257:00 amRNSNotice of AGM
14th May 20257:01 amRNSTransaction in Own Shares
14th May 20257:00 amRNSMonthly Valuation Update and Factsheet
13th May 20257:00 amRNSTransaction in Own Shares
12th May 20257:00 amRNSTransaction in Own Shares
9th May 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.